- Conditions
- Metastatic Urothelial Cancer, Unresectable Locally Advanced Urothelial Cancer
- Interventions
- Carboplatin + Gemcitabine, Cisplatin + Gemcitabine, Durvalumab, Tremelimumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 1,246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Bakersfield, California • Fullerton, California + 19 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1345–1368
of 1,975
matching trials from the local directory fallback.
- Conditions
- Degenerative Osteoarthritis
- Interventions
- Placebo Control, TG-C
- Biological
- Lead sponsor
- Kolon TissueGene, Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 535 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 37 more
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Neoplasm
- Interventions
- Laboratory Biomarker Analysis, Pharmacological Study, Temozolomide, Vorinostat
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2027
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 14 more
- Conditions
- Rett Syndrome
- Interventions
- TSHA-102
- Genetic
- Lead sponsor
- Taysha Gene Therapies, Inc.
- Industry
- Eligibility
- 2 Years to 3 Years · Female only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Chicago, Illinois • Boston, Massachusetts
- Conditions
- Diabetes Mellitus, Type 1, Insulin Dependent Diabetes, Pregnancy in Diabetics, Pregnancy, High-Risk
- Interventions
- Hybrid closed loop insulin delivery system
- Device
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Aurora, Colorado • Tampa, Florida + 6 more
- Conditions
- Atopic Dermatitis
- Interventions
- Ruxolitinib, Vehicle Cream
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Denver, Colorado + 17 more
- Conditions
- Cystic Fibrosis
- Interventions
- Ivacaftor, Placebo, RCT2100
- Drug · Other
- Lead sponsor
- ReCode Therapeutics
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Palo Alto, California + 10 more
- Conditions
- B-Cell Acute Lymphoblastic Leukemia
- Interventions
- CTL019
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 1 Year to 25 Years
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 25 more
- Conditions
- Acute Myeloid Leukemia, Down Syndrome, Myelodysplastic Syndrome, Myeloid Leukemia Associated With Down Syndrome, Myeloproliferative Neoplasm
- Interventions
- Asparaginase, Asparaginase Erwinia chrysanthemi, Cytarabine, Daunorubicin Hydrochloride, Etoposide, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride, Thioguanine
- Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 91 Days to 3 Years
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 169
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 131 more
- Conditions
- Genetic Disease
- Interventions
- Genome Informed Risk Assessment (GIRA) report
- Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 3 Years to 75 Years
- Enrollment
- 26,877 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2030
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Tempe, Arizona • Chicago, Illinois + 7 more
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- abiraterone acetate, olaparib
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 99 Years · Male only
- Enrollment
- 895 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 23 more
- Conditions
- AGA, Androgenetic Alopecia, Androgenetic Alopecia (AGA), Female Androgenetic Alopecia, Hair Loss
- Interventions
- Placebo, VDPHL01 BID, VDPHL01 QD
- Drug
- Lead sponsor
- Veradermics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 552 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 71
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fort Smith, Arkansas + 65 more
- Conditions
- Childhood Astrocytoma, Childhood Diffuse Intrinsic Pontine Glioma, Childhood Diffuse Midline Glioma, Childhood Glioblastoma, Childhood Malignant Glioma
- Interventions
- ATM Kinase Inhibitor AZD1390, Biospecimen Collection, Magnetic Resonance Imaging, Radiation Therapy, Survey Administration
- Drug · Procedure · Radiation + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 12 Months to 22 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- Buloxibutid, Placebo
- Drug
- Lead sponsor
- Vicore Pharma AB
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 378 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Redding, California • Sacramento, California + 19 more
- Conditions
- Progressive Relapsing Multiple Sclerosis, Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Interventions
- Placebo, Teriflunomide, Tolebrutinib
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 47 more
- Conditions
- Pre-Exposure Prophylaxis of HIV Infection
- Interventions
- Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF), Lenacapavir Injection, Lenacapavir Tablet
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 253 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • San Diego, California • Washington D.C., District of Columbia + 7 more
- Conditions
- Prostate Adenocarcinoma
- Interventions
- Bicalutamide, Buserelin, Darolutamide, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Radiation Therapy, Relugolix, Triptorelin
- Drug · Radiation
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 2,050 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 567
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 432 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Afimetoran, Placebo
- Drug · Other
- Lead sponsor
- Beeline Medicines Corporation
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Huntington Beach, California • La Jolla, California + 30 more
- Conditions
- Migraine
- Interventions
- Placebo for Ubrogepant, Ubrogepant
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 496 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 103
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 92 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Astegolimab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 40 Years to 90 Years
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 68
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Jasper, Alabama + 56 more
- Conditions
- Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, Glioblastoma, Glioblastoma (GBM), Gliosarcoma of Brain, Gliosarcoma, Adult
- Interventions
- C134
- Drug
- Lead sponsor
- James Markert, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- ISS, Noonan Syndrome, SGA, Turner Syndrome
- Interventions
- Somapacitan
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Sacramento, California • Centennial, Colorado + 3 more
- Conditions
- Low Grade Glioma, Neurofibromatosis Type 1, Visual Pathway Glioma
- Interventions
- Carboplatin, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Selumetinib Sulfate, Vincristine Sulfate
- Drug · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 125
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 101 more
- Conditions
- Breast Cancer
- Interventions
- Pertuzumab, Positron emission tomography (PET), Trastuzumab
- Drug · Procedure
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia • Indianapolis, Indiana + 6 more